Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience.

Date publication

décembre 2022

Journal

Clinical cancer research : an official journal of the American Association for Cancer Research

Auteurs

Membres identifiés du Cancéropôle Est :
Dr SIMAND Célestine

Tous les auteurs :
Marmouset V, Decroocq J, Garciaz S, Etienne G, Belhabri A, Bertoli S, Gastaud L, Simand C, Chantepie S, Uzunov M, Genthon A, Berthon C, Chiche E, Dumas PY, Vargaftig J, Salmeron G, Lemasle E, Tavernier E, Delage J, Loirat M, Morineau N, Blanc-Durand F, Pautier P, Vergé V, Auger N, Thomas M, Stefani L, Lepelley M, Boyer T, Thepot S, Gourin MP, Bourquard P, Duchmann M, Morice PM, Michallet M, Adès L, Fenaux P, Récher C, Dombret H, Pagès A, Marzac C, Leary A, Micol JB,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/36201165

Résumé

To provide insights into the diagnosis and management of therapy-related myeloid neoplasms (t-MN) following PARP inhibitors (PARPi).

Mots clés

Female, Humans, Poly(ADP-ribose) Polymerase Inhibitors, adverse effects, Ovarian Neoplasms, drug therapy, Carcinoma, Ovarian Epithelial, Mutation, Germ-Line Mutation, Neoplasms, Second Primary, diagnosis

Référence

Clin Cancer Res. 2022 12 1;28(23):5211-5220